Reply to B.M. Strebel

Affiliations

Comment

Fabrice Barlesi et al. J Clin Oncol. 2014.

. 2014 Feb 10;32(5):479-80.

doi: 10.1200/JCO.2013.53.7175. Epub 2013 Dec 30.

¹ Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille; Centre Investigation Clinique, Marseille, France.

No abstract available

Comment on

Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).
Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikström A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ. Barlesi F, et al. J Clin Oncol. 2013 Aug 20;31(24):3004-11. doi: 10.1200/JCO.2012.42.3749. Epub 2013 Jul 8. J Clin Oncol. 2013. PMID: 23835708 Clinical Trial.
When the abstract reports a well-tolerated treatment, the data should support it.
Strebel BM. Strebel BM. J Clin Oncol. 2014 Feb 10;32(5):478-9. doi: 10.1200/JCO.2013.52.5451. Epub 2013 Dec 30. J Clin Oncol. 2014. PMID: 24378416 No abstract available.